IRIS - Res&Arch Institutional Research Information System - Research & Archive

SPORTOLETTI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.676
AS - Asia 2.868
EU - Europa 2.833
SA - Sud America 502
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 9.943
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.580
SG - Singapore 1.281
IT - Italia 945
IE - Irlanda 577
CN - Cina 480
HK - Hong Kong 455
BR - Brasile 427
VN - Vietnam 291
RU - Federazione Russa 269
DE - Germania 215
FI - Finlandia 166
SE - Svezia 136
KR - Corea 132
UA - Ucraina 125
GB - Regno Unito 79
IN - India 52
RO - Romania 50
CA - Canada 45
FR - Francia 45
MX - Messico 42
AT - Austria 41
NL - Olanda 31
AR - Argentina 30
BE - Belgio 30
TR - Turchia 30
PL - Polonia 29
BD - Bangladesh 22
UZ - Uzbekistan 22
CZ - Repubblica Ceca 21
JP - Giappone 20
ZA - Sudafrica 18
CH - Svizzera 17
LT - Lituania 16
ES - Italia 14
EC - Ecuador 13
IQ - Iraq 13
PE - Perù 10
ID - Indonesia 8
CI - Costa d'Avorio 7
CL - Cile 7
IR - Iran 6
PK - Pakistan 6
AZ - Azerbaigian 5
IL - Israele 5
MA - Marocco 5
PT - Portogallo 5
KE - Kenya 4
KZ - Kazakistan 4
LB - Libano 4
NP - Nepal 4
PH - Filippine 4
PY - Paraguay 4
SC - Seychelles 4
AO - Angola 3
CO - Colombia 3
EG - Egitto 3
GR - Grecia 3
JO - Giordania 3
PA - Panama 3
PS - Palestinian Territory 3
SA - Arabia Saudita 3
UY - Uruguay 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AL - Albania 2
BO - Bolivia 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EU - Europa 2
GE - Georgia 2
IM - Isola di Man 2
LV - Lettonia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TW - Taiwan 2
UG - Uganda 2
AM - Armenia 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
CG - Congo 1
DJ - Gibuti 1
EE - Estonia 1
ET - Etiopia 1
GH - Ghana 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LY - Libia 1
ME - Montenegro 1
MK - Macedonia 1
MT - Malta 1
MZ - Mozambico 1
NG - Nigeria 1
Totale 9.933
Salva come PNG Salva come JPEG
Città #
Singapore 855
Chandler 594
Dublin 571
Perugia 478
Hong Kong 455
San Mateo 384
Boardman 207
Ashburn 198
Santa Clara 165
Dong Ket 140
Altamura 131
Seoul 129
Munich 117
Medford 107
Princeton 105
Lawrence 101
Beijing 94
Ann Arbor 81
Moscow 71
Wilmington 66
New York 65
Los Angeles 64
Andover 63
Helsinki 59
Jacksonville 58
Ho Chi Minh City 56
Turku 56
Piscataway 47
Bucharest 43
Hanoi 35
São Paulo 35
Brussels 30
Rome 30
Des Moines 27
Dearborn 26
Houston 26
Brooklyn 25
Redmond 25
The Dalles 25
Dallas 24
Foligno 23
Vienna 22
Hefei 21
Nuremberg 21
San Paolo di Civitate 20
Tokyo 20
Warsaw 20
Belo Horizonte 19
Shanghai 19
Norwalk 18
Mexico City 17
Montreal 17
Redwood City 17
Amsterdam 16
Assisi 15
London 15
Rio de Janeiro 15
San Francisco 15
Izmir 14
Saint Petersburg 14
Frankfurt am Main 13
Chicago 12
Guangzhou 12
Johannesburg 12
Menlo Park 12
Stockholm 12
Atlanta 11
Brno 11
Milan 11
Tashkent 11
Haiphong 10
Council Bluffs 9
Manchester 9
Orem 9
Phoenix 9
Toronto 9
Woodbridge 9
Collazzone 8
Denver 8
Falkenstein 8
Falls Church 8
Poplar 8
Abidjan 7
Boston 7
Changsha 7
Chennai 7
Mumbai 7
Tianjin 7
Tower Hamlets 7
Ankara 6
Brasília 6
Cambridge 6
Charlotte 6
Curitiba 6
Dhaka 6
Fairfield 6
Nanning 6
Olomouc 6
Paris 6
Porto Alegre 6
Totale 6.562
Salva come PNG Salva come JPEG
Nome #
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 157
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 152
Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation. 146
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice 143
Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia 141
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 141
Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction 133
A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis 132
Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. 124
BCOR gene alterations in hematological diseases 117
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 115
Wnt/beta-Catenin Signaling Induces Integrin alpha 4 beta 1 in T Cells and Promotes a Progressive Neuroinflammatory Disease in Mice 114
NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. 114
Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita 114
Mesenchymal cells: a vehicle for gene therapy 110
Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL 110
Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. 109
NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models 109
The NOTCH1/CD39 axis: A Treg trip-switch for GvHD 106
NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status 106
NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1 EPIGENETIC SILENCING IN A AML MOUSE MODEL 104
Clinical-Grade Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell Dependent Graft-versus-Leukemia Effect in Murine Models 104
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia 104
NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications 104
NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. 102
The radiosensitizer Silver nanoparticles effects are prevent to ion channel blocker DIDS in U251 human glioblastoma cell line. 101
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations 100
Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice 99
IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. 96
A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. 95
T regulatory cell separation for clinical application. 94
CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. 94
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity 93
Blockade of Oncogenic NOTCH1 With the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 93
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 93
Human stromal cells engineered with interleukin-7 enhance the survival of naive T lymphocytes. 92
BRAF mutations in hairy-cell leukemia. 92
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 92
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. 91
A novel NOTCH1 PEST domain mutation in a case of Chronic Lymphocytic Leukemia 91
Isolation and characterization of a new human T regulatory cell subset from peripheral blood CD4+ T lymphocyte 90
NPM1 AND FLT3-ITD MUTATIONS COOPERATE TO IMPAIR HEMATOPOIETIC STEM/PROGENITOR CELLS DIFFERENTIATION AND DEREGULATE GATA1 IN A MOUSE MODEL OF AML 90
Richter's transformation in the heart 90
Mutant NPM1 Maintains the Leukemic State through HOX Expression 89
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome 87
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 86
Interleukin-7-engineered mesenchymal cells: in vitro effects on naive T-cell population. 84
A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia 82
NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. 81
Mutational landscape of AML with normal cytogenetics: biological and clinical implications 81
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. 81
IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY 81
Glucocorticoidi-Induced TNFR family Related gene (GITR) enhances dendritic cell activity 80
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 80
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 80
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia 80
CURCUMIN EXHIBITS IN VITRO AND IN VIVO ANTI-LEUKEMIC ACTIVITY INTERFERING WITH THE NOTCH1 PATHWAY AND INDUCING ENDOPLASMIC RETICULUM STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 78
Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35 77
GSK3β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL 76
The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice 76
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML 74
Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses 73
BEPRIDIL IS A POTENT NOTCH1 INHIBITOR AND EFFICIENTLY INDUCES APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) CELLS in vitro AND in vivo 72
NOTCH and NF-κB interplay in chronic lymphocytic leukemia is independent of genetic lesion. 71
Synthesis and characterization of UiO-66 metal-organic frameworks nanoparticles and their evaluation as drug delivery carriers in U251 glioblastoma cells 70
Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia 69
Interleukin 7-engineered stromal cells: a new approach for hastening naive T cell recruitment 69
Mesenchymal cells recruit and regulate T regulatory cells. 69
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL 69
A NOVEL MECHANISM FOR NOTCH1 ACTIVATIONIN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS: INVOLVEMENT OF NOTCH1 ENDOSOMAL TRAFFICKING AND ALTERATIONS IN RAB PROTEINS 68
Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis. 68
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 68
A curious novel combination of nucleophosmin (Npm1) gene mutations leading to aberrant cytoplasmic dislocation of npm1 in acute myeloid leukemia (aml) 68
A pro-inflammatory environment in bone marrow of Treg transplanted patients matches with graft-versus-leukemia effect 67
A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells 67
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications 67
Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. 66
NPM1-mutated acute myeloid leukemia: from bench to bedside 66
Functions of the native NPM1 protein and its leukemic mutant 65
NOTCH-1 ACTIVATION AND SUBCLONAL MUTATION NEGATIVELY IMPACT ON CHRONIC LYMPHOCYTIC LEUKEMIA OUTCOMES 64
FLT3-targeted therapy restores GATA1 pathway function in NPM1/FLT3-ITD mutated acute myeloid leukaemia 64
Catalase prevents DNA damage and cationic current activation by silver nanoparticles in U251 human glioblastoma cell line 62
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience 62
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 61
A scale of "bad" co-mutations in NPM1-driven AML 60
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 60
Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia. 60
NOTCH1-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential 59
A DYSREGULATED, DRUGGABLE PP2A/AKT/GSK3 beta AXIS SUSTAINS NOTCH1 SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 58
Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. 58
The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein 56
The landscape of BRAF transcript and protein variants in human cancer. 54
Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis. 53
Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and tumorigenesis. 53
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia 52
Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics 52
NOTCH1 Aberrant Activation Is a Common Nonmutational Early Event in Chronic Lymphocytic Leukemia Hematopoietic Stem-Cells 52
NOTCH and Graft-Versus-Host Disease 52
Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions 51
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 51
Totale 8.576
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.071
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.071
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021350 0 0 0 0 0 31 37 29 47 21 35 150
2021/20221.312 48 376 9 44 26 9 18 226 30 138 210 178
2022/20231.946 111 371 18 183 140 195 11 85 708 8 81 35
2023/2024918 40 81 52 35 6 24 282 10 52 31 137 168
2024/20252.398 77 195 63 81 293 142 211 172 478 109 366 211
2025/20262.399 360 303 237 597 741 161 0 0 0 0 0 0
Totale 10.377